



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

September 11, 2023

Michael Jensen  
Chief Financial Officer  
Synlogic, Inc.  
301 Binney St., Suite 402  
Cambridge, MA 02142

**Re: Synlogic, Inc.**  
**Form 10-K for the fiscal year ended December 31, 2022**  
**Filed March 29, 2023**  
**File No. 001-37566**

Dear Michael Jensen:

We have limited our review of your filing to the financial statements and related disclosures and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response.

After reviewing your response to this comment, we may have additional comments.

Form 10-K for the fiscal year ended December 31, 2022

Management's Discussion and Analysis of Financial Condition and Results of Operations

Financial Overview

Research and Development Expense, page 83

1. Please revise your future filings to break out the amounts incurred for Internal research and development expenses by nature or type of expense (i.e. employee related expenses) for each period presented.

In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

You may contact Vanessa Robertson at 202-551-3649 or Daniel Gordon at 202-551-3486 with any questions.

Michael Jensen  
Synlogic, Inc.  
September 11, 2023  
Page 2

Sincerely,

Division of Corporation Finance  
Office of Life Sciences